Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more
Immunocore Holdings Ltd (IMCR) - Total Assets
Latest total assets as of September 2025: $1.10 Billion USD
Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) holds total assets worth $1.10 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Immunocore Holdings Ltd - Total Assets Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Immunocore Holdings Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Immunocore Holdings Ltd's total assets of $1.10 Billion consist of 92.1% current assets and 7.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.1% |
| Accounts Receivable | $83.10 Million | 8.2% |
| Inventory | $5.45 Million | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunocore Holdings Ltd's current assets represent 92.1% of total assets in 2024, an increase from 87.4% in 2018.
- Cash Position: Cash and equivalents constituted 45.1% of total assets in 2024, down from 63.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 8.2% of total assets.
Immunocore Holdings Ltd Competitors by Total Assets
Key competitors of Immunocore Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Immunocore Holdings Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Immunocore Holdings Ltd generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Immunocore Holdings Ltd is currently not profitable relative to its asset base.
Immunocore Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.00 | 3.78 | 2.78 |
| Quick Ratio | 5.97 | 3.76 | 2.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $852.50 Million | $ 739.66 Million | $ 97.93 Million |
Immunocore Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Immunocore Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.12 |
| Latest Market Cap to Assets Ratio | 1.30 |
| Asset Growth Rate (YoY) | 69.1% |
| Total Assets | $1.01 Billion |
| Market Capitalization | $1.31 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Immunocore Holdings Ltd's assets above their book value (1.30 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Immunocore Holdings Ltd's assets grew by 69.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immunocore Holdings Ltd (2018–2024)
The table below shows the annual total assets of Immunocore Holdings Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.01 Billion | +69.10% |
| 2023-12-31 | $597.00 Million | +13.33% |
| 2022-12-31 | $526.76 Million | +29.34% |
| 2021-12-31 | $407.28 Million | +106.54% |
| 2020-12-31 | $197.19 Million | -19.82% |
| 2019-12-31 | $245.94 Million | +25.62% |
| 2018-12-31 | $195.78 Million | -- |